Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 168

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors

Open access
Wilding, John P.H.·2014·Metabolism
DOI 10.1016/j.metabol.2014.06.018
Open this paper in CoChat — free account

Abstract

The kidneys play an important role in regulating glucose homeostasis through utilization of glucose, gluconeogenesis, and glucose reabsorption via sodium glucose co-transporters (SGLTs) and glucose transporters. The renal threshold for glucose excretion (RTG) is increased in patients with type 2 diabetes mellitus (T2DM), possibly due to upregulation of SGLT2 and SGLT1 expression. The resulting increase in renal glucose reabsorption is thought to contribute to the maintenance of hyperglycemia in patients with T2DM. Selective SGLT2 inhibitors reduce the RTG, thereby increasing glucosuria, and have demonstrated favorable efficacy and safety in patients with T2DM inadequately controlled with diet and exercise and other glucose-lowering treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2014.06.018

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 64

  1. Gerich, 2010, Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications, Diabet Med, 27, 136, 10.1111/j.1464-5491.2009.02894.x · DOI · Paper page
  2. Stumvoll, 1995, Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine, J Clin Invest, 96, 2528, 10.1172/JCI118314 · DOI · Paper page
  3. Gerich, 2000, Physiology of glucose homeostasis, Diabetes Obes Metab, 2, 345, 10.1046/j.1463-1326.2000.00085.x · DOI · Paper page
  4. Gerich, 2001, Renal gluconeogenesis: its importance in human glucose homeostasis, Diabetes Care, 24, 382, 10.2337/diacare.24.2.382 · DOI · Paper page
  5. Cersosimo, 1999, Insulin regulation of renal glucose metabolism in humans, Am J Physiol, 276, E78
  6. Meyer, 1998, Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism, Am J Physiol, 275, F915
  7. Meyer, 2003, Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans, Am J Physiol Endocrinol Metab, 285, E819, 10.1152/ajpendo.00145.2003 · DOI
  8. Meyer, 2002, Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis, Am J Physiol Endocrinol Metab, 282, E419, 10.1152/ajpendo.00032.2001 · DOI · Paper page
  9. Wright, 2001, Renal Na(+)-glucose cotransporters, Am J Physiol Renal Physiol, 280, F10, 10.1152/ajprenal.2001.280.1.F10 · DOI · Paper page
  10. Bakris, 2009, Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications, Kidney Int, 75, 1272, 10.1038/ki.2009.87 · DOI · Paper page
  11. Abdul-Ghani, 2011, Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes, Endocr Rev, 32, 515, 10.1210/er.2010-0029 · DOI · Paper page
  12. Bays, 2009, From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus, Curr Med Res Opin, 25, 671, 10.1185/03007990802710422 · DOI · Paper page
  13. Nair, 2010, Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus, J Clin Endocrinol Metab, 95, 34, 10.1210/jc.2009-0473 · DOI · Paper page
  14. Bailey, 2011, Renal glucose reabsorption inhibitors to treat diabetes, Trends Pharmacol Sci, 32, 63, 10.1016/j.tips.2010.11.011 · DOI · Paper page
  15. Polidori, 2013, Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study, Diabetes Care, 36, 2154, 10.2337/dc12-2391 · DOI · Paper page
  16. Polidori, 2013, Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus, J Clin Endocrinol Metab, 98, E867, 10.1210/jc.2012-4205 · DOI
  17. Liang, 2012, Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models, PLoS One, 7, e30555, 10.1371/journal.pone.0030555 · DOI · Paper page
  18. Rave, 2006, Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes—results of a hyperglycaemic glucose clamp study, Nephrol Dial Transplant, 21, 2166, 10.1093/ndt/gfl175 · DOI
  19. Ruhnau, 1997, Renal threshold for glucose in non-insulin-dependent diabetic patients, Diabetes Res Clin Pract, 36, 27, 10.1016/S0168-8227(97)01389-2 · DOI
  20. Wolf, 2009, Renal glucose excretion and tubular reabsorption rate related to blood glucose in subjects with type 2 diabetes with a critical reappraisal of the “renal glucose threshold” model, Horm Metab Res, 41, 600, 10.1055/s-0029-1220723 · doi:10.1055/s-0029-1220723
  21. Polidori, 2010, Canagliflozin lowers the renal threshold for glucose excretion in lean, obese and type 2 diabetic subjects [abstract], Diabetologia, 53, S350
  22. Devineni, 2012, Canagliflozin improves glycemic control over 28days in subjects with type 2 diabetes not optimally controlled on insulin, Diabetes Obes Metab, 14, 539, 10.1111/j.1463-1326.2012.01558.x · DOI · Paper page
  23. Farber, 1951, Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose, J Clin Invest, 30, 125, 10.1172/JCI102424 · DOI · Paper page
  24. Mogensen, 1971, Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects, Scand J Clin Lab Invest, 28, 101, 10.3109/00365517109090668 · DOI · Paper page
  25. Rahmoune, 2005, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes, Diabetes, 54, 3427, 10.2337/diabetes.54.12.3427 · DOI · Paper page
  26. Vestri, 2001, Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat, J Membr Biol, 182, 105, 10.1007/s00232-001-0036-y · DOI · Paper page
  27. Freitas, 2008, Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity, Endocrinology, 149, 717, 10.1210/en.2007-1088 · DOI · Paper page
  28. Tabatabai, 2009, Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats, Diabetes Res Clin Pract, 83, e27, 10.1016/j.diabres.2008.11.003 · DOI
  29. Turk, 1991, Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter, Nature, 350, 354, 10.1038/350354a0 · DOI · Paper page
  30. Calado, 2008, Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion, Nephrol Dial Transplant, 23, 3874, 10.1093/ndt/gfn386 · DOI
  31. Santer, 2003, Molecular analysis of the SGLT2 gene in patients with renal glucosuria, J Am Soc Nephrol, 14, 2873, 10.1097/01.ASN.0000092790.89332.D2 · DOI · Paper page
  32. Santer, 2010, Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target, Clin J Am Soc Nephrol, 5, 133, 10.2215/CJN.04010609 · DOI · Paper page
  33. Zambrowicz, 2012, LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial, Clin Pharmacol Ther, 92, 158, 10.1038/clpt.2012.58 · DOI · Paper page
  34. Kurosaki, 2013, Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data, Pharmacol Ther, 139, 51, 10.1016/j.pharmthera.2013.04.003 · DOI
  35. Miao, 2013, Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects, Drug Metab Dispos, 41, 445, 10.1124/dmd.112.049551 · DOI
  36. Ferrannini, 2013, A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes, Diabetes Obes Metab, 15, 721, 10.1111/dom.12081 · DOI · Paper page
  37. Devineni, 2013, Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus, J Clin Pharmacol, 53, 601, 10.1002/jcph.88 · DOI · Paper page
  38. Sha, 2011, Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects, Diabetes Obes Metab, 13, 669, 10.1111/j.1463-1326.2011.01406.x · DOI · Paper page
  39. Rosenstock, 2012, Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes, Diabetes Care, 35, 1232, 10.2337/dc11-1926 · DOI · Paper page
  40. Stein, 2012, Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes mellitus (T2DM) by a non-renal mechanism [abstract], Diabetes, 61
  41. Nomura, 2010, Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, J Med Chem, 53, 6355, 10.1021/jm100332n · DOI · Paper page
  42. Bode, 2013, Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial, Hosp Pract, 41, 72, 10.3810/hp.2013.04.1020 · DOI · Paper page
  43. Cefalu, 2013, Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52week results from a randomised, double-blind, phase 3 non-inferiority trial, Lancet, 382, 941, 10.1016/S0140-6736(13)60683-2 · DOI · Paper page
  44. Schernthaner, 2013, Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial, Diabetes Care, 36, 2508, 10.2337/dc12-2491 · DOI · Paper page
  45. Stenlöf, 2013, Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise, Diabetes Obes Metab, 15, 372, 10.1111/dom.12054 · DOI · Paper page
  46. Yale, 2013, Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease, Diabetes Obes Metab, 15, 463, 10.1111/dom.12090 · DOI · Paper page
  47. Lavalle-González, 2013, Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial, Diabetologia, 56, 2582, 10.1007/s00125-013-3039-1 · DOI · Paper page
  48. Wilding, 2013, Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial, Int J Clin Pract, 67, 1267, 10.1111/ijcp.12322 · DOI · Paper page
  49. Cefalu, 2013, Canagliflozin (CANA) demonstrates durable glycemic improvements over 104weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) [abstract], Diabetes, 62, LB18
  50. Komoroski, 2009, Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects, Clin Pharmacol Ther, 85, 520, 10.1038/clpt.2008.251 · DOI · Paper page
  51. Ferrannini, 2010, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care, 33, 2217, 10.2337/dc10-0612 · DOI · Paper page
  52. Bailey, 2010, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial, Lancet, 375, 2223, 10.1016/S0140-6736(10)60407-2 · DOI · Paper page
  53. Strojek, 2011, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial, Diabetes Obes Metab, 13, 928, 10.1111/j.1463-1326.2011.01434.x · DOI · Paper page
  54. Rosenstock, 2012, Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy, Diabetes Care, 35, 1473, 10.2337/dc11-1693 · DOI · Paper page
  55. Del Prato, 2013, Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data [abstract], Diabetes, 62, LB17
  56. Nicolle, 2014, Urinary tract infection in randomized Phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor, Postgrad Med, 126, 7, 10.3810/pgm.2014.01.2720 · DOI
  57. Johnsson, 2013, Urinary tract infections in patients with diabetes treated with dapagliflozin, J Diabetes Complications, 27, 473, 10.1016/j.jdiacomp.2013.05.004 · DOI · Paper page
  58. Johnsson, 2013, Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin, J Diabetes Complications, 27, 479, 10.1016/j.jdiacomp.2013.04.012 · DOI · Paper page
  59. Nyirjesy, 2014, Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies, Curr Med Res Opin, 30, 1109, 10.1185/03007995.2014.890925 · DOI
  60. Ptaszynska, 2012, Effect of dapagliflozin on renal function [abstract], Diabetes, 61, 1098-P
  61. Bailey, 2013, Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial, BMC Med, 11, 43, 10.1186/1741-7015-11-43 · DOI · Paper page
  62. Nauck, 2011, Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial, Diabetes Care, 34, 2015, 10.2337/dc11-0606 · DOI · Paper page
  63. Henry, 2013, Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study [abstract], Diabetes, 62, LB20
  64. Perkins, 2014, Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial, Diabetes Care, 37, 1480, 10.2337/dc13-2338 · DOI · Paper page

Cited by

See all 168

Metadata

Authors
Wilding, J. P. H.
Venue
Metabolism
Publisher
Elsevier BV
Published
2014-10
Volume
63
Issue
10
Pages
1228-1237
ISSN
0026-0495 (ISSN-L)
DOI
10.1016/j.metabol.2014.06.018
OpenAlex
W2066042413
Cited by
168
References
10
FWCI
14.60
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. https://app.cochat.ai/papers/10.1016/j.metabol.2014.06.018
The paper
Wilding, J. P. H. (2014). The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. https://doi.org/10.1016/j.metabol.2014.06.018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.